Sagimet Biosciences Inc. SGMT
10.89 USD +0.06 (+0.55%)
At closeNov 10, 2026, 4:00 PM EST
10.99 +0.10 +0.92%
After hours · Nov 10, 4:00 PM ET
10.48 Day range 10.99
4.50 52-week range 11.45
- YTD
- +83.95%
- 1 year
- +30.73%
News
benzinga.com Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
benzinga.com Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd.…- benzinga.com HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
benzinga.com Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26 Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.- benzinga.com Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38 Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.
- benzinga.com Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27 Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.
benzinga.com Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.- benzinga.com Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded…
- benzinga.com Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the "ATM Prospectus Supplement") related to the Company’s Series A common stock, par value $0.0001 per…
- benzinga.com Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive…
- benzinga.com Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
benzinga.com This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
benzinga.com Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18 Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.- benzinga.com Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71 Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
benzinga.com HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.- benzinga.com Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026 All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2026,with first patient to be enrolled shortly afterFOSTER CITY, Calif., Aug. 25, 2026 (GLOBE…
benzinga.com Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29 Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.- benzinga.com Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56 Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.
benzinga.com Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 18.75 percent increase over losses of…- benzinga.com Sagimet Biosciences Added To Broad-Market Russell 3000 Index And Small-Cap Russell 2000 Index Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the…
benzinga.com Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.- benzinga.com UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-associated-steatohepatitis-mash-in-adults
- benzinga.com Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trialPhase 1 data show rapid…
- benzinga.com Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12 Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $35 to $12.
- benzinga.com Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of…
- benzinga.com Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $49 Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $28 to $49.
- benzinga.com Guggenheim Maintains Buy on Sagimet Biosciences, Lowers Price Target to $25 Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27 to $25.
benzinga.com Why Is Sagimet Biosciences Stock Trading Higher On Monday? Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Sagimet Biosciences Prices Underwritten Offering Of 29,166,700 Shares Of Series A Common Stock At $6/Shr For Gross Proceeds Of ~$175M Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing…- benzinga.com Sagimet Biosciences Plans To Initiate Phase 3 Clinical Trial Of Denifanstat In Moderate To Severe Acne Patients For US In H2 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Informa Tech's digital businesses. TechTarget shares surged…
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.